Diphtheria Toxoid / Haemophilus B Conjugate (Prp-T) Vaccine / Pertussis, Acellular / Poliovirus Vaccine, Inactivated / Tetanus Toxoid Dosage

Medically reviewed by Drugs.com. Last updated on Nov 30, 2020.

Usual Pediatric Dose for Haemophilus influenzae Prophylaxis

0.5 mL intramuscularly at 2, 4, 6, and 15 to 18 months of age

Comments:
-The first dose may be given as early as 6 weeks of age.
-Four doses constitute a primary vaccination course against pertussis.
-Three doses constitute a primary vaccination course against diphtheria, tetanus, Haemophilus b, and poliomyelitis, with the fourth dose considered a booster against these diseases.
-This vaccine may be used to complete the first 4 doses of the 5 dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed [DTaP] series in infants who have received 1 or more DTaP doses and are also scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-This vaccine may be used in infants/children who have received 1 or more doses of another inactivated polio vaccine (IPV) or a Haemophilus b Conjugate vaccine (individual or combination vaccination) and are scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-When this vaccine is administered at the recommended ages, the Advisory Committee on Immunization Practices (ACIP) recommends an additional IPV booster dose at 4 to 6 years old, resulting in a 5 dose IPV series.

Usual Pediatric Dose for Poliomyelitis Prophylaxis

0.5 mL intramuscularly at 2, 4, 6, and 15 to 18 months of age

Comments:
-The first dose may be given as early as 6 weeks of age.
-Four doses constitute a primary vaccination course against pertussis.
-Three doses constitute a primary vaccination course against diphtheria, tetanus, Haemophilus b, and poliomyelitis, with the fourth dose considered a booster against these diseases.
-This vaccine may be used to complete the first 4 doses of the 5 dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed [DTaP] series in infants who have received 1 or more DTaP doses and are also scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-This vaccine may be used in infants/children who have received 1 or more doses of another inactivated polio vaccine (IPV) or a Haemophilus b Conjugate vaccine (individual or combination vaccination) and are scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-When this vaccine is administered at the recommended ages, the Advisory Committee on Immunization Practices (ACIP) recommends an additional IPV booster dose at 4 to 6 years old, resulting in a 5 dose IPV series.

Usual Pediatric Dose for Diphtheria Prophylaxis

0.5 mL intramuscularly at 2, 4, 6, and 15 to 18 months of age

Comments:
-The first dose may be given as early as 6 weeks of age.
-Four doses constitute a primary vaccination course against pertussis.
-Three doses constitute a primary vaccination course against diphtheria, tetanus, Haemophilus b, and poliomyelitis, with the fourth dose considered a booster against these diseases.
-This vaccine may be used to complete the first 4 doses of the 5 dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed [DTaP] series in infants who have received 1 or more DTaP doses and are also scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-This vaccine may be used in infants/children who have received 1 or more doses of another inactivated polio vaccine (IPV) or a Haemophilus b Conjugate vaccine (individual or combination vaccination) and are scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-When this vaccine is administered at the recommended ages, the Advisory Committee on Immunization Practices (ACIP) recommends an additional IPV booster dose at 4 to 6 years old, resulting in a 5 dose IPV series.

Usual Pediatric Dose for Pertussis Prophylaxis

0.5 mL intramuscularly at 2, 4, 6, and 15 to 18 months of age

Comments:
-The first dose may be given as early as 6 weeks of age.
-Four doses constitute a primary vaccination course against pertussis.
-Three doses constitute a primary vaccination course against diphtheria, tetanus, Haemophilus b, and poliomyelitis, with the fourth dose considered a booster against these diseases.
-This vaccine may be used to complete the first 4 doses of the 5 dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed [DTaP] series in infants who have received 1 or more DTaP doses and are also scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-This vaccine may be used in infants/children who have received 1 or more doses of another inactivated polio vaccine (IPV) or a Haemophilus b Conjugate vaccine (individual or combination vaccination) and are scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-When this vaccine is administered at the recommended ages, the Advisory Committee on Immunization Practices (ACIP) recommends an additional IPV booster dose at 4 to 6 years old, resulting in a 5 dose IPV series.

Usual Pediatric Dose for Tetanus Prophylaxis

0.5 mL intramuscularly at 2, 4, 6, and 15 to 18 months of age

Comments:
-The first dose may be given as early as 6 weeks of age.
-Four doses constitute a primary vaccination course against pertussis.
-Three doses constitute a primary vaccination course against diphtheria, tetanus, Haemophilus b, and poliomyelitis, with the fourth dose considered a booster against these diseases.
-This vaccine may be used to complete the first 4 doses of the 5 dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed [DTaP] series in infants who have received 1 or more DTaP doses and are also scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-This vaccine may be used in infants/children who have received 1 or more doses of another inactivated polio vaccine (IPV) or a Haemophilus b Conjugate vaccine (individual or combination vaccination) and are scheduled to receive the other antigens in this vaccine, but safety and immunogenicity of these mixed sequences have not been established.
-When this vaccine is administered at the recommended ages, the Advisory Committee on Immunization Practices (ACIP) recommends an additional IPV booster dose at 4 to 6 years old, resulting in a 5 dose IPV series.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
-Severe allergic reaction (e.g. anaphylaxis) after a previous dose of this vaccine or any other containing diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated polio vaccine, Haemophilus b vaccine, or any ingredient in this vaccine
-Encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizure) of unknown etiology within 7 days of a pertussis containing.
-Progressive neurologic disorder (including infantile spasms, uncontrolled epilepsy, progressive encephalopathy) after any pertussis-containing vaccine; do not administer until a treatment regimen has been established and the condition has stabilized.

Safety and efficacy have not been established in patients older than 5 years; this drug is not recommended for use in these patients.

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS) at: https://vaers.hhs.gov

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-This vaccine is supplied in two vials; be sure to administer the contents of both vials as directed in package labeling.
-The anterolateral aspect of the thigh is the preferred injection site in infants under 1 year.
-The deltoid may be used in older children.
-Do not administer in the gluteal area or other areas where there may be a major nerve trunk.
-For intramuscular use only; do not give intravenously or subcutaneously.

Storage requirements: Refrigerate; do not freeze.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

IV compatibility:
-Do not mix in the same syringe as other parenteral products.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer